NCT03267134

Brief Summary

The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent in patients with refractory open-angle glaucoma.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
217

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2017

Longer than P75 for not_applicable

Geographic Reach
5 countries

20 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2017

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

August 22, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 30, 2017

Completed
5.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 16, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 16, 2022

Completed
3.1 years until next milestone

Results Posted

Study results publicly available

January 14, 2026

Completed
Last Updated

January 14, 2026

Status Verified

December 1, 2025

Enrollment Period

5.4 years

First QC Date

August 22, 2017

Results QC Date

December 1, 2025

Last Update Submit

December 21, 2025

Conditions

Keywords

Glaucoma

Outcome Measures

Primary Outcomes (1)

  • Percentage of Subjects With Greater Than or Equal to a 20 Percent Decrease From Baseline in Mean Diurnal Intraocular Pressure (MDIOP) at Month 12 While Maintaining the Same or Fewer Number of Medications as at Baseline

    Intraocular pressure was measured using Goldmann Applanation tonometry. Three separate IOP measurements were taken over an 8-hour period and averaged together to achieve mean diurnal intraocular pressure.

    Baseline, Month 12

Secondary Outcomes (1)

  • Mean Change From Baseline in MDIOP at Month 12

    Baseline, Month 12

Study Arms (1)

Hydrus Microstent

EXPERIMENTAL

Hydrus Microstent implanted in the eye per the supplied Hydrus Microstent Instructions for Use and associated training. Only one eye (study eye) will be implanted.

Device: Hydrus MicrostentProcedure: Ophthalmic surgery

Interventions

Implantation of the Hydrus Microstent performed under either local or topical ophthalmic anesthesia

Hydrus Microstent

Device implanted into the Schlemm's canal of the eye to provide a natural outflow pathway for aqueous humor, leading to a reduction in intraocular pressure (IOP). The Hydrus Microstent is intended for lifetime use of the glaucoma patient.

Hydrus Microstent

Eligibility Criteria

Age45 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Open-angle glaucoma with optic nerve pathology;
  • BCVA of 20/80 or better in study eye;
  • Refractory glaucoma;

You may not qualify if:

  • Secondary glaucoma other than pseudoexfoliative and pigmentary glaucoma;
  • Acute angle closure, chronic angle closure, or congenial, malignant, or developmental glaucoma;
  • Pre-perimetric glaucoma;
  • Ocular hypertension
  • Shallow or flat anterior chamber;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (20)

Vold Vision

Fayetteville, Arkansas, 72704, United States

Location

Sacramento Eye Consultants

Sacramento, California, 95815, United States

Location

Eye Center of Northern Colorado

Fort Collins, Colorado, 80528, United States

Location

Ocala Eye

Ocala, Florida, 34474, United States

Location

Center for Sight

Venice, Florida, 34283, United States

Location

Stiles Eyecare

Overland Park, Kansas, 66213, United States

Location

Louisiana Eye and Laser Center

Alexandria, Louisiana, 71303, United States

Location

Washington University in St. Louis Ophthalmology

St Louis, Missouri, 63110, United States

Location

Scott & Christie and Associates

Cranberry Township, Pennsylvania, 16066, United States

Location

Texan Eye

Austin, Texas, 78731, United States

Location

Glaucoma Associates of Texas

Dallas, Texas, 75231, United States

Location

El Paso Eye Surgeons

El Paso, Texas, 79902, United States

Location

Ophthalmology Associates

Fort Worth, Texas, 76102, United States

Location

Vale-Asche Russell Clinical Research Center

Houston, Texas, 77030, United States

Location

R and R Research, LLC

San Antonio, Texas, 78229, United States

Location

The Eye Centers of Racine and Kenosha

Kenosha, Wisconsin, 53142, United States

Location

Clínica Oftalmológica

Barranquilla, 080020, Colombia

Location

Asian Eye Institute

Makati City, 1200, Philippines

Location

Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain

Location

Manchester Royal Eye Hospital

Manchester, M13 9WL, United Kingdom

Location

MeSH Terms

Conditions

Glaucoma, Open-AngleGlaucoma

Interventions

Ophthalmologic Surgical Procedures

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Intervention Hierarchy (Ancestors)

Surgical Procedures, Operative

Results Point of Contact

Title
Clinical Project Lead, CRD Surgical
Organization
Alcon Research, LLC

Study Officials

  • Clinical Project Lead, CRD Surgical

    Alcon Research, LLC

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 22, 2017

First Posted

August 30, 2017

Study Start

August 1, 2017

Primary Completion

December 16, 2022

Study Completion

December 16, 2022

Last Updated

January 14, 2026

Results First Posted

January 14, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations